OKYO Pharma Limited

NASDAQ:OKYO

Biotechnology

Healthcare
$1.10 +0.64%

+$0.01 today

Market cap
$57.73M
Beta
0.02
P/E (TTM)
-12.8
EPS (TTM)
-$0.12
52W Low $1.42High $3.35

Volume 0.24M

Average 0.07M

OKYO Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

OKYO Pharma LimitedNASDAQ: OKYO

Capital Expenditures · Q2 FY2026 · quarter ended Sep 2025

Capital expenditures declines year over year

Q2 FY2026 capital expenditures of $4 (cash outflow) fell 20.0% year over year. Over 3 fiscal years it compounded at -10.2% a year.

Context

  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2025
-$4— QoQ
Last fiscal yearMar 2025
-$1.21K+40166.7% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.0%——
1 year+40166.7%——
3-year CAGR-10.2%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(1.21K) USD
Year-over-year change
-40166.7%

Capital Expenditures vs competitors

How OKYO compares with its peers on the latest reported figures

  • OKYO's FY2025 capital expenditures of $1.21K is the 8th largest of the 10 companies compared; the peer median is $39K.
  • Its year-over-year change of +40166.7% is the highest of 8, against a peer median of -37.7%.
  • Over three fiscal years its annual growth of -10.2% compares with a peer median of -35.0%.
OKYO Competitors Peer median
Capital Expenditures for OKYO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$1.73M -37.7%-19.2%1.1%
IMMXImmix Biopharma, Inc.LTM Mar 2026$697.7K -26.1%——
WHWKWhitehawk Therapeutics IncLTM Dec 2025$552K -66.6%+7.5%7.7%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$112K -95.7%-40.3%—
CLNNClene Inc.LTM Mar 2026$39K +874.9%-80.4%29.1%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$34K -81.2%——
TLSATiziana Life Sciences LtdFY2025$21K +38.3%——
OKYOOKYO Pharma LimitedFY2025$1.21K +40166.7%-10.2%—
COYACoya Therapeutics, Inc.LTM Mar 2026$3 ——0.0%
SLGLSol-Gel Technologies Ltd.LTM Jun 2024$0 —-35.0%0.0%
Peer median (excluding OKYO) $39K-37.7%-35.0%1.1%

Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Net Income(3.38M)(6.22M)(13.28M)(16.83M)(7.97M)
Depreciation & Amortization13.11K2.33K3.8K3.87K2.56K
Deferred Income Tax92.95K(9.41K)250.35K00
Stock-Based Compensation544.39K1.72M1.27M1.12M734.99K
Change in Working Capital1.04M(1.02M)4.14M2.67M3.63M
Accounts Receivables205.07K27.38K167.72K440.26K(90.4K)
Inventory00000
Accounts Payables0(297.99K)02.8M0
Other Working Capital839.78K(753.25K)3.98M(570.08K)3.72M
Other Non-Cash Items83.01K61.72K(84.16K)3.54M1.8M
Operating Cash Flow(1.6M)(5.47M)(7.7M)(9.49M)(1.81M)
Capital Expenditures(6.94K)(1.67K)(5.92K)(3)(1.21K)
Acquisitions (Net)00000
Purchases of Investments(11.15K)0000
Sales of Investments00000
Other Investing Activities(21)0000
Investing Cash Flow(18.11K)(1.67K)(5.92K)0(1.21K)
Debt Repayment7.58M02M0950K
Common Stock Issued230.02K1.43M7.32M6.21M1.71M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities15.87K725.51K9.32M01.71M
Financing Cash Flow7.83M2.15M9.32M6.21M2.66M
Effect of Forex Changes445.22K(872.14K)(277.54K)63.5K(109.55K)
Net Change in Cash6.65M(4.19M)1.34M(3.22M)734.05K
Free Cash Flow(1.61M)(5.47M)(7.7M)(9.49M)(1.81M)

OKYO Pharma Limited

NASDAQ:OKYO

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.